Latest News

Wednesday, April 01, 2015 | Product Releases, FCI Ophthalmics

InVitria Injection Assistant Now Available for Popular AMD Injections

The InVitria intravitreal injection assistant is now available in several models to accommodate the syringes of various popular injectable therapeutic agents for AMD, according to a news release from …

Read the full story

Wednesday, April 01, 2015 | Clinical Trials

Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

Kala Pharmaceuticals announced positive top-line results from a phase 3 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, for the treatment of inflammation and p…

Read the full story

Wednesday, April 01, 2015 | Clinical Trials

Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

Kala Pharmaceuticals announced positive top-line results from a phase 2 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, in patients with dry eye disease, accor…

Read the full story

Wednesday, April 01, 2015 | Management/Leadership

New President, Stan Dickerson, OD, Plans to Maintain SECO’s Prominence With SECO University

As the new president of the Southern Council of Optometrists, Stan Dickerson, OD, plans to maintain SECO’s prominence as a leader in providing optometric education, he told Vision Monday in his …

Read the full story

Tuesday, March 31, 2015 | Avedro

FDA Does Not Approve Avedro's Corneal Cross-Linking Platform Application, Requesting Additional Information

Despite a joint FDA advisory panel in February recommending approval of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking, th…

Read the full story

Tuesday, March 31, 2015 | Clinical Trials, Ocata Therapeutics

Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies

Ocata Therapeutics announced that the company has completed dosing of its phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of …

Read the full story

Tuesday, March 31, 2015 | Product Releases, Optos

First Shipments of California Devices for the Ophthalmology Market Commence

Optos announced that it has commenced first shipments of California, the second device from its next generation ultra-widefield (UWF) imaging platform, according to a company news release. California …

Read the full story

Tuesday, March 31, 2015 | Earnings & Financials, Abbott Medical Optics

Abbott Moves to Sell Roughly One-Third of Mylan Stake

Mylan shares were down as much as 5.4% on Monday after the company announced an underwritten public offering of shares held by Abbott Laboratories. According to Mylan, the offering of ordinary shares …

Read the full story

Tuesday, March 31, 2015 | Clinical Trials, Retina

Neurotech Announces FDA Acceptance of Investigational New Drug Application and Clinical Trial Initiation of Novel Therapy for Wet AMD

Neurotech Pharmaceuticals announced that the FDA has accepted and communicated Neurotech's ability to proceed with its investigational new drug (IND) application to conduct a phase 2 clinical stud…

Read the full story

Monday, March 30, 2015 | Blindness, Partnerships

Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness

Avalanche Biotechnologies announced that it has entered into an exclusive license agreement with the University of Washington in Seattle to develop products based on Avalanche’s proprietary Ocul…

Read the full story

Monday, March 30, 2015 | Glaucoma, Product Releases, IRIDEX

Iridex Granted US Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries

Iridex Corp. announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable device intended to replace certain suturing techniques in eye su…

Read the full story

Monday, March 30, 2015 | Acquisitions/Mergers

Teva to Buy Auspex for $3.5 Billion to Boost Neurology Arm

Teva Pharmaceutical Industries Ltd. agreed to buy Auspex Pharmaceuticals Inc. for about $3.5 billion in cash to gain drugs that curb tics and other movement disorders. Teva will begin a tender offer o…

Read the full story

Monday, March 30, 2015 | Health Care

White House Plan to Fight Superbugs Promotes Drug Research

The Obama administration released a plan Friday to halt the spread of antibiotic-resistant bacteria in the wake of a deadly outbreak at a Los Angeles hospital in February. The plan seeks to reduce the…

Read the full story

Monday, March 30, 2015 | Blindness

First Vision-Restoring "Bionic Eye" Implant Performed in Hawaii

Groundbreaking bionic retinal implant surgery has been performed in Honolulu by a team at the Eye Surgery Center of Hawaii. The procedure is the first of its kind in the Asia-Pacific region to help re…

Read the full story

Friday, March 27, 2015 | Product Releases

Eye Photo Systems Launches New Toric Alignment by Osher Software for Slit Lamp Photography

Eye Photo Systems, manufacturer of the EC 100 and EC 90 high-resolution anterior segment cameras, has launched the TAO (Toric Alignment by Osher) software tool to assist with intraoperative…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $31.24  -0.32% 
 Akorn, Inc. $47.40  -0.23% 
 Alimera Sciences, Inc. $4.77  -4.79% 
 Allergan, Inc. $240.22  0.00% 
 Avalanche $39.06  -3.60% 
 Bayer $151.70  0.95% 
 Can-Fite Biopharma $2.27  1.79% 
 Carl Zeiss Meditec $24.27  -0.31% 
 Cooper Companies, Inc. $186.59  -0.44% 
 Escalon Medical Corp. $1.40  3.70% 
 Essilor International $115.00  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.99  0.00% 
 InSite Vision, Inc. $0.17  -9.09% 
 IRIDEX Corporation $10.43  -2.34% 
 Johnson & Johnson $99.15  -1.44% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $63.25  0.83% 
 Merck & Company, Inc. $56.86  -1.08% 
 NicOx $1.86  -1.22% 
 NovaBay Pharmaceuticals, Inc. $0.73  5.83% 
 Novartis AG Common Stock $99.86  1.27% 
 Ocular Therapeutix $41.27  -1.70% 
 Ophthotech Corporation $46.48  -0.11% 
 Quantel $2.99  -1.97% 
 Regeneron $441.18  -2.28% 
 Roche $34.54  0.48% 
 STAAR Surgical Company $7.32  -1.48% 
 TearLab Corporation $2.00  0.50% 
 Thrombogenics $5.40  0.00% 
 Topcon Corporation $24.71  0.00% 
 Valeant Pharmaceuticals $197.39  -0.62% 
 Xoma $3.56  -2.20%